title: The JUPITER trial: How will it change clinical practice?
abstract: Several studies have shown that baseline levels of high-sensitivity C-reactive protein (hs-CRP) in apparently healthy men and women are predictive of future cardiovascular events. In primary prevention, hs-CRP levels could indicate which primary prevention patients are at higher risk and might benefit from preventive statin therapy. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) aimed to determine whether treatment with rosuvastatin 20 mg/d would reduce the rate of first major cardiovascular events among apparently healthy individuals with low-density lipoprotein cholesterol (LDL-C) levels below 130 mg/dL, but with hs-CRP levels of 2 mg/L or higher. At the time of study closure, it was found that treatment with rosuvastatin significantly reduced the primary composite endpoint by 44% as compared with placebo. Results of the JUPITER trial clearly suggest that patients with elevated hs-CRP stand to benefit from statin therapy, regardless of their LDL-C level.
authors: Division of Cardiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
authors: Karol E
authors: KE
authors: Watson
mesh_terms: D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D011322:Primary Prevention; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein